The company has a presence in more than 76 countries across North America, Central & South America, Europe, China, CIS, Asia Pacific, Middle East and Africa through its own sales force and local teams in various countries.


Additionally, Claris enjoys a unique position in the regulated markets because of its know-how and expertise in manufacturing injectable products. The company has identified regulated markets comprising North America, the European Union, Central and East Europe, the Far East, Australasia and the Middle East, as one of its major drivers for growth in the coming years.  


Claris is in the process of establishing an extensive marketing and distribution network in all the regulated markets and has also filed its dossiers for product registration in key regulated markets. To spearhead its sales and distribution activities in Europe and the USA, the company has established its own subsidiaries Claris Lifesciences Limited (U.K.) and Claris Lifesciences Inc., USA. To cater to the high potential Chinese market, the company also established a representative office in China.


A significant share of the company's revenues come from international operations, and several major brands like Profol (propofol) , Hestar (hydroxyethyl starch) and anti-infectives like Ciprox/Ciprocina (ciprofloxacin), are widely recognized and accepted globally.


Our teams in international markets include sales, marketing and support people, ably complemented by a strong network of distribution partners. This level of infrastructure in international markets helps us meet the demands of our international customers including aid agencies, large corporate hospitals and institutions.